The use of antibiotics in the treatment of pediatric varicella patients: real-world evidence from the multi-country MARVEL study in Latin America & Europe.
dc.date.accessioned | 2019-08-08T15:23:44Z | |
dc.date.available | 2019-08-08T15:23:44Z | |
dc.date.created | 2019-08-08T15:23:44Z | |
dc.date.issued | 2019 | |
dc.identifier | https://hdl.handle.net/20.500.12866/7129 | |
dc.identifier | https://doi.org/10.1186/s12889-019-7071-z | |
dc.description.abstract | BACKGROUND: Varicella is a highly contagious childhood disease. Generally benign, serious complications necessitating antibiotic use may occur. The objective of this study was to characterize the rate, appropriateness and patterns of real-world antibiotic prescribing for management of varicella-associated complications, prior to universal varicella vaccination (UVV) implementation. METHODS: Pooled, post-hoc analysis of 5 international, multicenter, retrospective chart reviews studies (Argentina, Hungary, Mexico, Peru, Poland). Inpatient and outpatient primary pediatric (1-14 years) varicella cases, diagnosed between 2009 and 2016, were eligible. Outcomes, assessed descriptively, included varicella-associated complications and antibiotic use. Three antibiotic prescribing scenarios were defined based on complication profile in chart: evidence of microbiologically confirmed bacterial infection (Scenario A); insufficient evidence confirming microbiological confirmation (Scenario B); no evidence of microbiological confirmation (Scenario C). Stratification was performed by patient status (inpatient vs. outpatient) and country. RESULTS: Four hundred one outpatients and 386 inpatients were included. Mean (SD) outpatient age was 3.6 (2.8) years; inpatient age was 3.1 (2.8) years. Male gender was predominant. Overall, 12.2% outpatients reported >/=1 infectious complication, 3.7% >/=1 bacterial infection, and 0.5% >/=1 microbiologically confirmed infection; inpatient complication rates were 78.8, 33.2 and 16.6%, respectively. Antibiotics were prescribed to 12.7% of outpatients and 68.9% of inpatients. Among users, beta-lactamases (class), and clindamycin (agent), dominated prescriptions. Scenario A was assigned to 3.9% (outpatients) vs 13.2% (inpatients); Scenario B: 2.0% vs. 6.0%; Scenario C: 94.1% vs. 80.8%. CONCLUSIONS: High rates of infectious complications and antibiotic use are reported, with low rates of microbiological confirmation suggesting possible antibiotic misuse for management of varicella complications. | |
dc.language | eng | |
dc.publisher | BioMed Central | |
dc.relation | BMC Public Health | |
dc.relation | 1471-2458 | |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es | |
dc.rights | info:eu-repo/semantics/restrictedAccess | |
dc.subject | adolescent | |
dc.subject | Adolescent | |
dc.subject | Anti-Bacterial Agents | |
dc.subject | Anti-Bacterial Agents/therapeutic use | |
dc.subject | antiinfective agent | |
dc.subject | Antimicrobial stewardship | |
dc.subject | bacterial infection | |
dc.subject | Bacterial Infections | |
dc.subject | Bacterial Infections/drug therapy/microbiology | |
dc.subject | beta lactamase | |
dc.subject | beta-Lactamases | |
dc.subject | beta-Lactamases/therapeutic use | |
dc.subject | chickenpox | |
dc.subject | Chickenpox | |
dc.subject | Chickenpox/drug therapy/epidemiology/virology | |
dc.subject | child | |
dc.subject | Child | |
dc.subject | Child, Preschool | |
dc.subject | clindamycin | |
dc.subject | Clindamycin | |
dc.subject | Clindamycin/therapeutic use | |
dc.subject | Delivery of Health Care | |
dc.subject | Delivery of Health Care/standards | |
dc.subject | Drug Prescriptions | |
dc.subject | Drug Prescriptions/statistics & numerical data | |
dc.subject | Europe | |
dc.subject | Europe/epidemiology | |
dc.subject | female | |
dc.subject | Female | |
dc.subject | health care delivery | |
dc.subject | hospital patient | |
dc.subject | hospitalization | |
dc.subject | Hospitalization | |
dc.subject | human | |
dc.subject | Humans | |
dc.subject | infant | |
dc.subject | Infant | |
dc.subject | Inpatients | |
dc.subject | Latin America | |
dc.subject | Latin America/epidemiology | |
dc.subject | male | |
dc.subject | Male | |
dc.subject | microbiology | |
dc.subject | Observation study | |
dc.subject | outpatient | |
dc.subject | Outpatients | |
dc.subject | Pediatrics | |
dc.subject | preschool child | |
dc.subject | prescription | |
dc.subject | Retrospective Studies | |
dc.subject | retrospective study | |
dc.subject | South and Central America | |
dc.subject | standards | |
dc.subject | statistics and numerical data | |
dc.subject | Varicella | |
dc.subject | virology | |
dc.title | The use of antibiotics in the treatment of pediatric varicella patients: real-world evidence from the multi-country MARVEL study in Latin America & Europe. | |
dc.type | info:eu-repo/semantics/article |